Purple Biotech (PPBT) Cash from Operations (2017 - 2025)
Purple Biotech has reported Cash from Operations over the past 6 years, most recently at 4214000.0 for Q4 2022.
- Quarterly Cash from Operations fell 18.94% to 4214000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 16735000.0 through Dec 2022, down 12.49% year-over-year, with the annual reading at 5656000.0 for FY2025, 60.63% up from the prior year.
- Cash from Operations was 4214000.0 for Q4 2022 at Purple Biotech, down from 3621000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2907000.0 in Q3 2021 and troughed at 6726000.0 in Q4 2020.
- The 5-year median for Cash from Operations is 3700000.0 (2022), against an average of 4240636.36.
- Year-over-year, Cash from Operations tumbled 103.14% in 2020 and then surged 47.32% in 2021.
- A 5-year view of Cash from Operations shows it stood at 4998000.0 in 2018, then skyrocketed by 33.75% to 3311000.0 in 2019, then crashed by 103.14% to 6726000.0 in 2020, then surged by 47.32% to 3543000.0 in 2021, then fell by 18.94% to 4214000.0 in 2022.
- Per Business Quant, the three most recent readings for PPBT's Cash from Operations are 4214000.0 (Q4 2022), 3621000.0 (Q3 2022), and 3700000.0 (Q2 2022).